Pembrolizumab, Ipilimumab and Nivolumab reduces cardiac pAMPK and IL-10, increases vascular NF-kB expression and levels of IL-1b, IL-2 and IL-6 in myocardial tissue
Nicola Maurea(Cancer Institute (WIA)), Vincenzo Quagliariello(Cancer Institute (WIA)), Fabrizio Maurea(Federico II University Hospital), Simona Buccolo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Ciro Cipullo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andrea Paccone(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), M Passariello, Martina Iovine(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Annabella Di Mauro(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), C De Lorenzo, Antonietta Caronna(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale")
Cited by 1
Related Papers
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
|Cardiovascular Diabetology|2021|368
Trastuzumab Adjuvant Chemotherapy and Cardiotoxicity in Real-World Women With Breast Cancer
|Journal of Cardiac Failure|2011|116
Metabolic syndrome affects breast cancer risk in postmenopausal women: National Cancer Institute of Naples experience
|Cancer Biology & Therapy|2010|108
Resveratrol in Cancer Patients: From Bench to Bedside
|International Journal of Molecular Sciences|2020|105
Ranolazine Protects from Doxorubicin-Induced Oxidative Stress and Cardiac Dysfunction
|European Journal of Heart Failure|2014|92